FILTER
FILTERED INTERVIEW RESULTS
Steve Tallant
SENIOR DIRECTOR, SOLUTION MARKETING GROUP AT SYSTECH, A SOLUTIONS DIVISION OF MARKEM-IMAJE
"We are taking a physical supply chain and creating a digital twin of products and data moving through the chain."
Tim Tyson
CHAIRMAN AND CEO, TRIRX PHARMACEUTICAL SERVICES
"Our focus on capacity utilization, market demand, and strategic acquisitions will be key drivers of TriRx's growth in the coming year."
Trevor Caswell
CHAIRMAN, PHARMA.AERO
"Pharma.Aero is a unique collaborative platform connecting life sciences shippers and service providers to achieve reliable end-to-end air transport for pharmaceutical cargo."
Denise Juliano
GROUP VICE PRESIDENT, LIFE SCIENCES, PREMIER INC.
"Our technology and data capabilities help researchers and providers gain insights into health inequities and support strategies and solutions to advance health equity."
Cory Lewis
CEO, PRESIDENT AND CO-FOUNDER, INCOG BIOPHARMA SERVICES
"Wrapping up Q1 in 2023 we are now above 80 employees with a facility that is cGMP production ready and actively manufacturing commercial PPQ batches for one of our biopharma clients."
Katrin Rupalla
CEO, YMMUNOBIO
"Based on our in vivo data for our lead CEACAM1/5 antibody YB-200, we have obtained orphan drug status from FDA for the treatment of liver cancer."
Stefan Randl & Paul Spencer
HEAD OF DRUG SUBSTANCE (SR), HEAD OF DRUG DELIVERY & PRODUCT (PS), EVONIK HEALTH CARE
"The US leads innovation, so if you are not heavily invested there in pharma, you are in trouble. Lots of our clients are shifting their production from Asia, so the US will remain critical to Evonik Health Care’s growth."
Roger Erickson
CEO AND FOUNDER, INTERBIOME
"We want to pioneer a commodity utility approach for needed areas of pharmaceutical manufacturing, and make that available as a sustainable platform that any country can start with and innovate from."
Jan Kengelbach
CEO, AENOVA GROUP
"Experienced CDMOs can provide companies with access to new formulation and technology methods that improve the bioavailability of difficult-to-formulate compounds."
Donna LaVoie
PRESIDENT AND CEO, LAVOIEHEALTHSCIENCE
"Companies should be ready to address hostile short-selling and unsolicited takeover bids, develop rapid responses to special meetings and activist demands, and vigorously engage with institutional shareholders, proxy advisory firms, and potential regulators."
MACIG
SPANISH
SUBSCRIBE TO OUR NEWSLETTER
RECENT PUBLICATIONS
Latin America Petrochemicals and Chemicals 2024 - Digital Interactive
The Latin America Petrochemicals and Chemicals 2024 report, produced in alliance with APLA, explores the current state of these industries, the challenges they face, and the opportunities they offer.
The Latin America Petrochemicals and Chemicals 2024 report, produced in alliance with APLA, explores the current state of these industries, the challenges they face, and the opportunities they offer.
PARTNER EVENTS
SUBSCRIBE TO OUR
NEWSLETTER
- Get GBR content delivered to your inbox
- Receive industry based news
- Completely free, e-mail only
